ASND.US Ascendis Pharma AS

Healthcare Biotechnology USA Stocks
276.96 USD
Close of Nov 13, 2026
188.08 282.15
Market cap
USD 18.2B
P/E
18.2x
P/B
10.44x
ROE
80.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ASND.US undervalued?

Graham number
Price276.96
Graham value95.30
Premium190.6%

ASND.US trades 190.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ascendis Pharma AS fundamental analysis

No fundamental analysis for Ascendis Pharma AS yet.

Ascendis Pharma AS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ascendis Pharma AS

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease produc…

Full company profile